NEW YORK – PinkDx emerged from stealth mode Thursday, announcing a $40 million series A financing that it plans to use to develop molecular diagnostic tests for gynecologic cancers using a multiomics and machine learning approach.

纽约——PinkDx周四从隐形模式中脱颖而出，宣布了一笔4000万美元的a系列融资，计划使用多组学和机器学习方法开发妇科癌症的分子诊断测试。

The financing was co-led by Catalio Capital Management, LP, and The Production Board. Other investors include Mountain Group Partners, Byers Capital, and Mayo Clinic.

融资由Catalio Capital Management、LP和制作委员会共同领导。其他投资者包括Mountain Group Partners、Byers Capital和Mayo Clinic。

'This funding, along with our best-in-class expertise, a proven discovery and development approach, and our commitment to clinical rigor, will enable us to solve critical challenges that today prevent women from receiving the best healthcare possible,' said Bonnie Anderson, the company's cofounder, chairwoman, and CEO..

该公司联合创始人、董事长兼首席执行官邦妮·安德森（BonnieAnderson）说：“这笔资金，加上我们一流的专业知识、经过验证的发现和开发方法，以及我们对临床严谨性的承诺，将使我们能够解决当今阻碍女性获得最佳医疗保健的关键挑战。”

Anderson is the cofounder and prior CEO of diagnostics firm Veracyte, which pioneered the Afirma test, intended to reduce unnecessary invasive procedures in the evaluation of potentially cancerous thyroid nodules.

安德森是诊断公司Veracyte的联合创始人和前任首席执行官，该公司是Afirma测试的先驱，旨在减少评估潜在癌性甲状腺结节时不必要的侵入性程序。

For PinkDx, the goal is similar — to improve diagnostic outcomes for women who present with vague gynecological cancer symptoms by developing molecular tests that can serve as alternatives to invasive and painful diagnostic procedures.

对于PinkDx来说，目标是类似的-通过开发分子检测来改善患有模糊妇科癌症症状的女性的诊断结果，这些分子检测可以替代侵入性和痛苦的诊断程序。